Strategies for recruitment of stem cells to treat myocardial infarction

Muhammad Shafiq, Sang Hoon Lee, Youngmee Jung, Soo Hyun Kim

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Heart failure is one of the most prominent causes of morbidity and mortality worldwide. According to the World Health Organization, coronary artery disease and myocardial infarction (MI) are responsible for 29% of deaths worldwide. MI results in obstruction of the blood supply to the heart and scar formation, and causes substantial death of cardiomyocytes in the infarct zone followed by an inflammatory response. Current treatment methodologies of MI and heart failure include organ transplantation, coronary artery bypass grafting, ventricular remodeling, cardiomyoplasty, and cellular therapy. Each of these methodologies has associated risks and benefits. Cellular cardiomyoplasty is a viable option to decrease the fibrosis of infarct scars, adverse post-ischemic remodeling, and improve heart function. However, the low rate of cell survival, shortage of cell sources and donors, tumorigenesis, and ethical issues hamper full exploitation of cell therapy for MI treatment. Consequently, the mobilization and recruitment of endogenous stem/progenitor cells from bone marrow, peripheral circulation, and cardiac tissues has immense potential through harnessing the host’s own reparative capacities that result from interplay among cytokines, chemokines, and adhesion molecules. Therapeutic treatments to enhance the mobilization and homing of stem cells are under development. In this review, we present state-of-the-art approaches that are being pursued for stem cell mobilization and recruitment to regenerate infarcted myocardium. Potential therapeutic interventions and delivery strategies are discussed in detail.

Original languageEnglish
Pages (from-to)1584-1597
Number of pages14
JournalCurrent Pharmaceutical Design
Volume21
Issue number12
Publication statusPublished - 2015

Fingerprint

Stem Cells
Myocardial Infarction
Cardiomyoplasty
Hematopoietic Stem Cell Mobilization
Heart Failure
Cicatrix
Therapeutics
Ventricular Remodeling
Organ Transplantation
Cell- and Tissue-Based Therapy
Chemokines
Cardiac Myocytes
Ethics
Coronary Artery Bypass
Coronary Artery Disease
Cause of Death
Cell Survival
Myocardium
Carcinogenesis
Fibrosis

Keywords

  • Angiogenesis
  • Cardiac tissue engineering
  • Drug delivery
  • Stem cell recruitment

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Strategies for recruitment of stem cells to treat myocardial infarction. / Shafiq, Muhammad; Lee, Sang Hoon; Jung, Youngmee; Kim, Soo Hyun.

In: Current Pharmaceutical Design, Vol. 21, No. 12, 2015, p. 1584-1597.

Research output: Contribution to journalArticle

Shafiq, Muhammad ; Lee, Sang Hoon ; Jung, Youngmee ; Kim, Soo Hyun. / Strategies for recruitment of stem cells to treat myocardial infarction. In: Current Pharmaceutical Design. 2015 ; Vol. 21, No. 12. pp. 1584-1597.
@article{482088f312ae42119b61fe320dc0fff4,
title = "Strategies for recruitment of stem cells to treat myocardial infarction",
abstract = "Heart failure is one of the most prominent causes of morbidity and mortality worldwide. According to the World Health Organization, coronary artery disease and myocardial infarction (MI) are responsible for 29{\%} of deaths worldwide. MI results in obstruction of the blood supply to the heart and scar formation, and causes substantial death of cardiomyocytes in the infarct zone followed by an inflammatory response. Current treatment methodologies of MI and heart failure include organ transplantation, coronary artery bypass grafting, ventricular remodeling, cardiomyoplasty, and cellular therapy. Each of these methodologies has associated risks and benefits. Cellular cardiomyoplasty is a viable option to decrease the fibrosis of infarct scars, adverse post-ischemic remodeling, and improve heart function. However, the low rate of cell survival, shortage of cell sources and donors, tumorigenesis, and ethical issues hamper full exploitation of cell therapy for MI treatment. Consequently, the mobilization and recruitment of endogenous stem/progenitor cells from bone marrow, peripheral circulation, and cardiac tissues has immense potential through harnessing the host’s own reparative capacities that result from interplay among cytokines, chemokines, and adhesion molecules. Therapeutic treatments to enhance the mobilization and homing of stem cells are under development. In this review, we present state-of-the-art approaches that are being pursued for stem cell mobilization and recruitment to regenerate infarcted myocardium. Potential therapeutic interventions and delivery strategies are discussed in detail.",
keywords = "Angiogenesis, Cardiac tissue engineering, Drug delivery, Stem cell recruitment",
author = "Muhammad Shafiq and Lee, {Sang Hoon} and Youngmee Jung and Kim, {Soo Hyun}",
year = "2015",
language = "English",
volume = "21",
pages = "1584--1597",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Strategies for recruitment of stem cells to treat myocardial infarction

AU - Shafiq, Muhammad

AU - Lee, Sang Hoon

AU - Jung, Youngmee

AU - Kim, Soo Hyun

PY - 2015

Y1 - 2015

N2 - Heart failure is one of the most prominent causes of morbidity and mortality worldwide. According to the World Health Organization, coronary artery disease and myocardial infarction (MI) are responsible for 29% of deaths worldwide. MI results in obstruction of the blood supply to the heart and scar formation, and causes substantial death of cardiomyocytes in the infarct zone followed by an inflammatory response. Current treatment methodologies of MI and heart failure include organ transplantation, coronary artery bypass grafting, ventricular remodeling, cardiomyoplasty, and cellular therapy. Each of these methodologies has associated risks and benefits. Cellular cardiomyoplasty is a viable option to decrease the fibrosis of infarct scars, adverse post-ischemic remodeling, and improve heart function. However, the low rate of cell survival, shortage of cell sources and donors, tumorigenesis, and ethical issues hamper full exploitation of cell therapy for MI treatment. Consequently, the mobilization and recruitment of endogenous stem/progenitor cells from bone marrow, peripheral circulation, and cardiac tissues has immense potential through harnessing the host’s own reparative capacities that result from interplay among cytokines, chemokines, and adhesion molecules. Therapeutic treatments to enhance the mobilization and homing of stem cells are under development. In this review, we present state-of-the-art approaches that are being pursued for stem cell mobilization and recruitment to regenerate infarcted myocardium. Potential therapeutic interventions and delivery strategies are discussed in detail.

AB - Heart failure is one of the most prominent causes of morbidity and mortality worldwide. According to the World Health Organization, coronary artery disease and myocardial infarction (MI) are responsible for 29% of deaths worldwide. MI results in obstruction of the blood supply to the heart and scar formation, and causes substantial death of cardiomyocytes in the infarct zone followed by an inflammatory response. Current treatment methodologies of MI and heart failure include organ transplantation, coronary artery bypass grafting, ventricular remodeling, cardiomyoplasty, and cellular therapy. Each of these methodologies has associated risks and benefits. Cellular cardiomyoplasty is a viable option to decrease the fibrosis of infarct scars, adverse post-ischemic remodeling, and improve heart function. However, the low rate of cell survival, shortage of cell sources and donors, tumorigenesis, and ethical issues hamper full exploitation of cell therapy for MI treatment. Consequently, the mobilization and recruitment of endogenous stem/progenitor cells from bone marrow, peripheral circulation, and cardiac tissues has immense potential through harnessing the host’s own reparative capacities that result from interplay among cytokines, chemokines, and adhesion molecules. Therapeutic treatments to enhance the mobilization and homing of stem cells are under development. In this review, we present state-of-the-art approaches that are being pursued for stem cell mobilization and recruitment to regenerate infarcted myocardium. Potential therapeutic interventions and delivery strategies are discussed in detail.

KW - Angiogenesis

KW - Cardiac tissue engineering

KW - Drug delivery

KW - Stem cell recruitment

UR - http://www.scopus.com/inward/record.url?scp=84930913734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930913734&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 1584

EP - 1597

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 12

ER -